Sorafenib (BAY 43-9006) - Moligand™, 10mM in DMSO , Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibito, Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibitor of fibroblast growth factor receptor 1;Inhibitor o

CAS: 284461-73-0 Cat. No.: S408543 Molecular Weight: 464.83 EC Number: 608-209-4
AVAILABLE TO ORDER
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
NSC-724772 | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
S408543-1ml
2
$53.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 58 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Information

Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor ofRaf-1andB-RafwithIC50of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibitsVEGFR-2,VEGFR-3,PDGFR-β,Flt-3andc-KITwith IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respective
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis.

In vivo

Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts.
Cell Data

cell lines:

Concentrations:Dissolved in DMSO, final concentrations ~10 μM

Incubation Time:72 hours

Powder Purity:≥99%

Specifications

Synonyms
NSC-724772 | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
Specifications & Purity
Moligand™, 10mM in DMSO
Biochemical and Physiological Mechanisms
Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 n
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibitor of fibroblast growth factor receptor 1;Inhibitor o
Names and Identifiers
Isomeric SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Molecular Weight 464.83
Reaxy-Rn 9666200
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9666200&ln=

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Associated Targets(Human)
EPHB4 Tchem Ephrin type-B receptor 4 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
DDR2 Tchem Discoidin domain-containing receptor 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
EGFR Tclin Epidermal growth factor receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CSF1R Tclin Macrophage colony-stimulating factor 1 receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CDK8 Tchem Cyclin-dependent kinase 8 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CDK19 Tchem Cyclin-dependent kinase 19 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
DDR1 Tchem Epithelial discoidin domain-containing receptor 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RAF1 Tclin RAF proto-oncogene serine/threonine-protein kinase (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RET Tclin Proto-oncogene tyrosine-protein kinase receptor Ret (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FLT4 Tclin Vascular endothelial growth factor receptor 3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
EPHX2 Tchem Bifunctional epoxide hydrolase 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HIPK4 Tchem Homeodomain-interacting protein kinase 4 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FGFR1 Tclin Fibroblast growth factor receptor 1 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
TEK Tclin Angiopoietin-1 receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDGFRB Tclin Platelet-derived growth factor receptor beta (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
BRAF Tclin Serine/threonine-protein kinase B-raf (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ARAF Tchem Serine/threonine-protein kinase A-Raf (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
FLT1 Tclin Vascular endothelial growth factor receptor 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KDR Tclin Vascular endothelial growth factor receptor 2 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HTR2B Tclin 5-hydroxytryptamine receptor 2B (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KIT Tclin Mast/stem cell growth factor receptor Kit (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MAPK3 Tchem Mitogen-activated protein kinase 3 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MAPK14 Tchem Mitogen-activated protein kinase 14 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MAP3K20 Tchem Mitogen-activated protein kinase kinase kinase 20 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
SolubilitySolubility (25°C) In vitro DMSO: 50 mg/mL (200.53 mM); Ethanol: 50 mg/mL (200.53 mM); Water: Insoluble;
Documents & Articles
Citations of This Product
References
1. Tongge Li, Shihui Wang, Qianhui Ling, Junyi Sun, Ning Yang, Zhanglei Fu, Zhaoyuan Zhang, Si Chen, Yanfei Wang, Ni Yu, Yafei Wang, Zhexuan Ding, Haodong Liu, Yanwei Jia, Yifang Wang, Xingcai Zhang.  (2025)  Cell Viability, Drug Screening, and Mechanism Study Under Mild Phototherapy Integrated Chemotherapy (PIC).  Advanced Science,      [PMID:40883257] [10.1002/advs.202502836]
2. Huimin Xie, Lin Ma, Xiaoli He, Songsong Zhao, Jin Wang, Ao Zhu, Changming Liu, Olga Piskareva, Chao Deng, Fenghua Meng, Mi Liu.  (2025)  Elevating MHC I expression on tumor cells by nanovesicles loading tyrosine kinase inhibitors can improve the efficacy of cancer vaccines.  Frontiers in Immunology,      [PMID:41019037] [10.3389/fimmu.2025.1653533]
3. Mengting Tong, Guangpeng Chen, Yong Dong, Yubin Pan, Yanan Xue, Da Li.  (2025)  A stepwise responsive Au-SS-PEG/Sor/ATPaptamer/LHRH-MPGΔNLS drug delivery vector system for overcoming drug resistance in immunotherapy of hepatocellular carcinoma.  Nanoscale Advances,      [PMID:40936736] [10.1039/d5na00056d]
4. Qinglian Hu, Liwang Xu, Xiaoyu Huang, Yuxuan Duan, Dongchang Sun, Zhengwei Fu, Yunfen Ge.  (2023)  Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.  BIOMACROMOLECULES,      [PMID:37938159] [10.1021/acs.biomac.3c00971]
5. Xi Chen, Ning Zhu, Yajie Wu, Ye Zhang, Yuxuan Zhang, Kaiwen Jin, Zhiyi Zhou, Guang Chen, Jiabing Wang.  (2023)  Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.  PHYTOMEDICINE,      [PMID:38537439] [10.1016/j.phymed.2023.155317]
6. Ye Yuan, Chunyu Tian, Qi Wang, Xinyu Qiu, Yufang Wang, Hulin Jiang, Jifu Hao, Yujing He.  (2023)  Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy.  Advanced Healthcare Materials,      [PMID:37458333] [10.1002/adhm.202301292]
7. Peifeng Wang, Yang Du, Xingyang Zhao, Yueyang Hu, Tianjun Zhou, Xiaolong Liang, Chihua Fang, Jie Tian.  (2023)  2-Methoxyestradiol loaded mesoporous polydopamine nanoprobes for hypoxia alleviation and sorafenib synergistic treatment of hepatocellular carcinoma.  MATERIALS & DESIGN,      [PMID:] [10.1016/j.matdes.2023.112137]
8. Yufei Pan, Jing Guan, Yujing Gao, Yuejie Zhu, Huantong Li, Hua Guo, Qianyi He, Zhu Guan, Zhenjun Yang.  (2023)  Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects.  Molecular Therapy-Nucleic Acids,      [PMID:37251692] [10.1016/j.omtn.2023.04.028]
9. Jing-Qing Le, Fang Yang, Xun-Huan Song, Ke-Ke Feng, Ling-Wu Tong, Meng-Die Yin, Wen-Zhong Zhang, Ying-Qi Lin, Hui Wu, Jing-Wei Shao.  (2023)  A hemoglobin-based oxygen-carrying biomimetic nanosystem for enhanced chemo-phototherapy and hypoxia alleviation of hepatocellular carcinoma.  JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY,      [PMID:] [10.1016/j.jiec.2023.03.050]
10. Yao Li, Mengying Liu, Yan Zheng, Zheng Wang, Yanjun Zhao.  (2023)  Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:36931212] [10.1016/j.jcis.2023.03.057]
11. Shuai Wang, Jian-Tao Shi, Xing-Rong Wang, Hong-Xia Mu, Xue-Ting Wang, Kai-Yan Xu, Qing-Shan Wang, Shi-Wu Chen.  (2023)  1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.  BIOORGANIC CHEMISTRY,      [PMID:36773456] [10.1016/j.bioorg.2023.106412]
12. Chunmei Lai, Bingchen Zhang, Dongmiao Li, Xiarong Tan, Bangyue Luo, Jiangwen Shen, Linyan Li, Jingwei Shao.  (2022)  Rational design of a minimum nanoplatform for maximizing therapeutic potency: Three birds with one stone.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:36599242] [10.1016/j.jcis.2022.12.157]
13. Hu Xiaomeng, He Yuchao, Han Zhiqiang, Liu Wei, Liu Dongming, Zhang Xihao, Chen Lu, Qi Lisha, Chen Liwei, Luo Yi, Li Qiang, Chen Peng, Wu Qiang, Zhu Xiaolin, Guo Hua.  (2022)  PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma.  Cell Death & Disease,  13  (11): (1-12).  [PMID:36446769] [10.1038/s41419-022-05448-7]
14. Xing-Rong Wang, Shuai Wang, Hong-Xia Mu, Kai-Yan Xu, Xue-Ting Wang, Jian-Tao Shi, Qi-Hang Cui, Li-Wen Zhang, Shi-Wu Chen.  (2022)  Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,      [PMID:36242985] [10.1016/j.ejmech.2022.114821]
15. Wang Chonggao, Cheng Xiaolan, Peng Hao, Zhang Yewei.  (2022)  NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma.  Nanoscale Research Letters,  17  (1): (1-16).  [PMID:36125619] [10.1186/s11671-022-03729-w]
16. An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li.  (2022)  Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma.  Nanomaterials,  12  (18): (3191).  [PMID:36144982] [10.3390/nano12183191]
17. Liyue Zhou, Qiangwei Liang, Yifan Li, Yongjing Cao, Juan Li, Jiayu Yang, Jinxia Liu, Jiawei Bi, Yanhua Liu.  (2022)  Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.  Acta Biomaterialia,      [PMID:36087869] [10.1016/j.actbio.2022.08.065]
18. Wenjie Feng, Wanrui Shi, Ze Wang, Yanqi Cui, Xinxin Shao, Shuwei Liu, Li Rong, Yi Liu, Hao Zhang.  (2022)  Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification.  ACS Applied Materials & Interfaces,      [PMID:35944147] [10.1021/acsami.2c11130]
19. Zaigang Zhou, Jiashe Chen, Yu Liu, Chunjuan Zheng, Wenjuan Luo, Lele Chen, Shen Zhou, Zhiming Li, Jianliang Shen.  (2022)  Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy.  Acta Pharmaceutica Sinica B,      [PMID:36386474] [10.1016/j.apsb.2022.07.023]
20. Chen Zibo, Yuan Tao, Yan Fangjie, Ye Song, Xie Qin, Zhang Bo, Lin Nengmin, He Qiaojun, Yang Bo, Zhu Hong.  (2022)  CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.  BMC CANCER,  22  (1): (1-9).  [PMID:35440025] [10.1186/s12885-022-09520-5]
21. Yuehua Wang, Zhenjie Wang, Fei Jia, Qing Xu, Zhilin Shu, Junlin Deng, Aimin Li, Meng Yu, Zhiqiang Yu.  (2022)  CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment.  Bioactive Materials,      [PMID:35386453] [10.1016/j.bioactmat.2022.01.003]
22. Jie Cui, Jiatao Liu, Lulu Fan, Yue Zhu, Bei Zhou, Yu Wang, Wei Hua, Wei Wei, Guoping Sun.  (2020)  A zinc finger family protein, ZNF263, promotes hepatocellular carcinoma resistance to apoptosis via activation of ER stress-dependent autophagy.  Translational Oncology,      [PMID:32898766] [10.1016/j.tranon.2020.100851]
23. Longfa Kou, Rui Sun, Xinyu Jiang, Xinlu Lin, Huirong Huang, Shihui Bao, Youting Zhang, Chao Li, Ruijie Chen, Qing Yao.  (2020)  Tumor Microenvironment-Responsive, Multistaged Liposome Induces Apoptosis and Ferroptosis by Amplifying Oxidative Stress for Enhanced Cancer Therapy.  ACS Applied Materials & Interfaces,      [PMID:32459093] [10.1021/acsami.0c03564]
24. Haiqiu Wu, Cun Wang, Jiaxin Sun, Luyan Sun, Jiaxun Wan, Siying Wang, Dishui Gu, Chengtao Yu, Chen Yang, Jia He, Zihao Zhang, Yuanyuan Lv, Hui Wang, Ming Yao, Wenxin Qin, Changchun Wang, Haojie Jin.  (2019)  Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.  ACS Applied Materials & Interfaces,      [PMID:31682099] [10.1021/acsami.9b18086]
25. Wenhui Gao, Xiaoting Jia, Jinjun Wu, Ying Song, Jiang Yin, Meimei Zhang, Ni Qiu, Xiaoyan Li, Peng Wu, Xiaoxiao Qi, Zhongqiu Liu.  (2019)  Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,      [PMID:] [10.1016/j.jddst.2019.101349]
26. Lu Bin, Chen Xiao-bing, Hong Yu-cai, Zhu Hong, He Qiao-jun, Yang Bo, Ying Mei-dan, Cao Ji.  (2019)  Identification of PRDX6 as a regulator of ferroptosis.  ACTA PHARMACOLOGICA SINICA,  40  (10): (1334-1342).  [PMID:31036877] [10.1038/s41401-019-0233-9]
27. Jun-Shan Liu, Chu-Ying Huo, Hui-Hui Cao, Chun-Lin Fan, Jian-Yang Hu, Li-Juan Deng, Zi-Bin Lu, Hua-Yi Yang, Lin-Zhong Yu, Zhi-Xian Mo, Zhi-Ling Yu.  (2019)  Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.  PHYTOMEDICINE,      [PMID:31039533] [10.1016/j.phymed.2019.152843]
28. Gao Ningning, Zhong Jingjing, Wang Xiaodong, Jin Zhenchao, Li Wang, Liu Yu, Diao Yuwen, Wang Zhulin, Jiang Wenqi, Jin Guangyi.  (2016)  Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.  Scientific Reports,  (1): (1-9).  [PMID:28000738] [10.1038/srep39598]
29. Chun-Mei Lai, Jia Xu, Bing-Chen Zhang, Shao-Hua He, Jing-Wei Shao.  (2024)  A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma.  CHEMICAL ENGINEERING JOURNAL,      [PMID:] [10.1016/j.cej.2024.148976]
30. Wenlong Huang, Bo Jin, Haobing Gong, Nawab Ali, Duoduo Jiang, Tongtong Shan, Liangshun Zhang, Jia Tian, Weian Zhang.  (2024)  A tumor Microenvironment-triggered protein-binding Near-infrared-II Theranostic nanoplatform for Mild-Temperature photothermal therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:39577235] [10.1016/j.jcis.2024.11.049]
31. Taosha Jin, Haiyang Wang, Ihsan Ullah, Wenjiao Xie, Taian Lin, Qiaoling Tan, Xiaoyu Pan, Youyong Yuan.  (2025)  A Wireless Operated Flexible Bioelectronic Microneedle Patch for Actively Controlled Transdermal Drug Delivery.  ADVANCED MATERIALS,      [PMID:39906918] [10.1002/adma.202417136]
32. Hongwei Xiang, Bin Shen, Chunmei Zhang, Rui Li.  (2024)  Bioactive Nanoliposomes for Enhanced Sonodynamic-Triggered Disulfidptosis-Like Cancer Cell Death via Lipid Peroxidation.  International Journal of Nanomedicine,      [PMID:39246429] [10.2147/IJN.S464178]
33. Yuanxin Pian, Yan Hao, Yuxin Guo, Shiqi Wu, Saijiao Tang, Jiaqi Li, Xinya Lu, Xiaoya Sun, Zhaowen Tan, Tianyu Zhu, Yuxiang Tang, Defeng Xu, Hang Hu.  (2025)  Exploration of using α-crocin for drug encapsulation and delivery.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,      [PMID:] [10.1016/j.jddst.2025.106716]
34. Xiaoxuan Li, Hongyun Zhang, Yufei Deng, Fang qian, Xiaohui Zhang, Shuiping Ding, Xiaoying Hou, Hongzhi Du.  (2024)  Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:39743053] [10.1016/j.ijbiomac.2024.139357]
35. Yonggang Lv, Zhenghang Chen, Shuai Wang, Meizhen Zou.  (2025)  Macrophage-Mediated Liquid Metal Nanoparticles for Enhanced Tumor Accumulation and Inhibition.  ACS Biomaterials Science & Engineering,      [PMID:39855913] [10.1021/acsbiomaterials.4c01130]
36. Rui-Rui Zhao, Ju-Hong Wu, Ling-Wu Tong, Jin-Yu Li, Yu-sheng Lu, Jing-Wei Shao.  (2024)  Multifunctional Metal-coordinated Co-assembled Carrier-free Nanoplatform Based on Dual-drugs for Ferroptosis-mediated Cocktail Therapy of Hepatocellular Carcinoma Growth and Metastasis.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:38244494] [10.1016/j.jcis.2024.01.066]
37. Fanqi Meng, Lei Chen, Haoran Chen, Meili Shen, Guangyi Wang, Yulei Chang.  (2024)  Multiple Stimuli-Responsive Micelles for Photo/ROS/pH-Triggered Chemo/Photo/Ferroptosis Therapy of Colorectal Cancer.  ACS Applied Nano Materials,      [PMID:] [10.1021/acsanm.4c05216]
38. Xing Gao, Hongwei Cheng, Minglei Teng, Hongrui Zhang, Hu Chen, Songnan Qu, Gang Liu.  (2025)  Optimizing interventional therapy: A homogeneous lipiodol formulation of Tirapazamine and Sorafenib responsive to post-embolization microenvironment.  JOURNAL OF CONTROLLED RELEASE,      [PMID:39880038] [10.1016/j.jconrel.2025.01.074]
39. Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, Zhi Xiong, Shirong Peng, Bingheng Li, Ruilin Zhuang, Jun Wu, Hai Huang.  (2024)  Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy.  ACS Biomaterials Science & Engineering,      [PMID:38850557] [10.1021/acsbiomaterials.4c00345]
40. Lu-Yao Zheng, Yan-Xin Da, Xiu Luo, Xiao Zhang, Zhi-Jie Sun, De-Li Dong.  (2024)  Sorafenib extends the lifespan of C. elegans through mitochondrial uncoupling mechanism.  FREE RADICAL BIOLOGY AND MEDICINE,      [PMID:38360276] [10.1016/j.freeradbiomed.2024.02.008]
41. Zhenghao Zhou, Cong Li, Shuai Cui, Shian Sun, Shaowei Zhu, Qing Yu, Ning Ding, Hao Hong, Dongzhi Yang.  (2024)  Synergistic therapy for melanoma via bioactive compounds derived metal-phenolic networks.  CHEMICAL ENGINEERING JOURNAL,      [PMID:] [10.1016/j.cej.2024.150831]
42. Chunfang Qin, Hao Wang, Hongyan Cui, Yue Wang, Ming Zhang, Haidong Li, Yuchen Liu, Jingyun Wang, Qixian Chen, Yan Zhao.  (2024)  Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:38850862] [10.1016/j.jcis.2024.06.010]
43. Li Xiang, Yuting Qin, Lei Li, Xianjing Xiang, Wenhui Zhang, Qiangqiang Jiao, Yaru Shao, Xinqiong Huang, Meichun Wu, Tianle Zhou, Yukang Lin, Yuping Chen.  (2024)  Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,      [PMID:39653289] [10.1016/j.ijpharm.2024.125058]
44. Cao Ji, Chen Xiaobing, Jiang Li, Lu Bin, Yuan Meng, Zhu Difeng, Zhu Hong, He Qiaojun, Yang Bo, Ying Meidan.  (2020)  DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase.  Nature Communications,  11  (1): (1-15).  [PMID:32144268] [10.1038/s41467-020-15109-y]
45. Zilin Li, Yan Wang, Jiahui Hu, Jingyang Du, Huizong Nie, Yiling Xi, Yue Huang, Kexin Wang, Kaixuan Zhang, Qiuran Xu, Liyan Cheng, Dongsheng Huang, Linglan Tu.  (2025)  USP28 Knockdown and Small Molecule Inhibitors Promote KRT1 Destabilization and Sensitize Hepatocellular Carcinoma Cells to Sorafenib.  EXPERIMENTAL CELL RESEARCH,      [PMID:40222446] [10.1016/j.yexcr.2025.114558]
46. Qijun Du, Hongwei Jiang, Di Wu, Changlong Song, Wenqi Hu, Qinrui Lu, Chenwei Sun, Jie Liu, Guohua Wu, Shuqi Wang.  (2025)  Radiation-Activated Cobalt-Based Zeolite Imidazolate Frameworks for Tumor Multitherapy.  Biomaterials Research,      [PMID:40236956] [10.34133/bmr.0164]
47. Wang Zexuan, Guo Yaoyu, Hu Kefei, He Tingjiang, Qin Tong, Zhang Ludan, Xu Fang, Xu Yuanzhi, Cheng Mingjiao, Zhang Jintao, Zhao Qianwei.  (2025)  Hepatocellular carcinoma cells downregulate PGAM2 via SIRT2-mediated deacetylation modification to enhance aerobic glycolysis.  npj Precision Oncology,  (1): (1-13).  [PMID:40379975] [10.1038/s41698-025-00930-9]
48. Yujie Wang, Zhaoyou Chu, Peisan Wang, Tao Li, Yu Jin, Silong Wu, Xiaowei Song, Weinan Zhang, Miaomiao Yang, Zhengbao Zha, Haisheng Qian, Yan Ma.  (2025)  Dual-ferroptosis induction-based microneedle patches for enhanced chemodynamic/photothermal combination therapy against triple-negative breast cancer.  Acta Pharmaceutica Sinica B,      [PMID:40893692] [10.1016/j.apsb.2025.05.034]
49. Ying Xu, Xiaojun Cai, Jianrong Wu, Yuanyi Zheng, Yaotai Wang.  (2025)  Colonization of Engineered Bacteria Enhanced Lipid Nanomedicine Accumulation in Tumors for Sonodynamic Immunotherapy,.  Materials Today Bio,      [PMID:40585038] [10.1016/j.mtbio.2025.101943]
50. Dong Wang, Mengrong Li, Tingting Dai, Xiangyu Zhang, Di Chen.  (2025)  In-syringe polypropylene fiber-supported liquid-phase microextraction followed by LC-MS/MS for rapid and sensitive determination of tyrosine kinase inhibitors in plasma.  MICROCHEMICAL JOURNAL,      [PMID:] [10.1016/j.microc.2025.114222]
51. Feifei Han, Haiping Wang, Li Wang, Limei Fan, Sibei Peng, Xiaoying Hou, Xiji Shu, Binlian Sun, Yuchen Liu.  (2025)  Carrier-Free Silibinin/Sorafenib Microparticles Alleviate Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Fatty Acid Metabolism.  International Journal of Nanomedicine,      [PMID:40462832] [10.2147/IJN.S515107]
52. Cheng-Lei Li, Wen-Zhong Zhang, Rui-Rui Zhao, Jing-Qing Le, Bing-Chen Zhang, Huan-Zhang Xie, Yu-Sheng Lu, Jing-Wei Shao.  (2025)  Synergistic ferroptosis-photo-chemo to disrupt redox homeostasis for augmenting cancer chemoimmunotherapy.  COLLOIDS AND SURFACES B-BIOINTERFACES,      [PMID:40602268] [10.1016/j.colsurfb.2025.114908]
53. Huiti Li, Ying Xu, Yimin Zheng, Zian Xue, Qingqing Li, Xinglong Jia, Lietao Weng, Lulu Jiang, Xiaoxue Ruan, Rong Zhang, Yue Yin, Liying Zhou, Fuyuan Li, He Huang, Jin Li, Minjia Tan, Jia Fan, Jiabin Cai, Guoqiang Chen, Lu Zhou.  (2025)  CBX4 acetoacetylation as an inhibitory mechanism of HIF-1α activity.  Cell Chemical Biology,      [PMID:41045931] [10.1016/j.chembiol.2025.09.005]
54. Ying Xiang, Jinyu Zheng, Xinlu Zhao, Lina Zhou, Qiong Yan, Yichun Ma, Yue Zhou, Ping Jiang, Yi Fang, Wenjun Li, Yinya Pan, Hongji Tao, Wenying Li, Fan Xiang, Yang Hua, Yuyi Li, Chang Zheng, Weihong Ge, Yuhong Li, Simin Yan, Yun Zhu, Guifang Xu.  (2025)  Sodium Butyrate Enhances Sorafenib-Induced Ferroptosis and Immunogenic Cell Death by Modulating IRF2-Oasl2-cGAS Pathway in Colorectal Cancer.  Materials Today Bio,      [PMID:41281652] [10.1016/j.mtbio.2025.102498]
55. Hao Dong, Yuan Gao, Dongyue Jiang, Chenjie Feng, Xinyue Gu, Xiyunyi Cai, Yulin Liu, Guangyu Zhang, Jiacheng Wen, Weiwei Diao, Ying Zhou, Ruixin Li, Dayang Xu, Weijia Xie, Liang Wu.  (2025)  Synthesis and Biological Evaluation of a Caffeic Acid Phenethyl Ester Derivatives as Anti-Hepatocellular Carcinoma Agents via Inhibition of Mitochondrial Respiration and Disruption of Cellular Metabolism.  Cancers,  18  (1): (92).  [PMID:41514605] [10.3390/cancers18010092]
56. Wang Dong, Li Mengrong, Zhang Xiangyu, Chai Shiwei, Chen Di.  (2026)  Ultrasonic-assisted magnetic sorbent–wrapped stick dip extraction enables batch-scale and green LC-MS/MS analysis of tyrosine kinase inhibitors in plasma.  ANALYTICAL AND BIOANALYTICAL CHEMISTRY,      [PMID:41575510] [10.1007/s00216-026-06335-2]
57. Yong Huang, Tao Quan, Bowen Li, Chaohui Zhen, Haiqian Zhang, Zhiyao Li, Chongzhi Wu, Rui Liang, Lihe Sun, Xin Xie.  (2026)  Ferroptosis-sensitizing nanoprodrug system for synergistic therapy of triple-negative breast cancer.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,      [PMID:41650740] [10.1016/j.jcis.2026.140048]
58. Jia-Rui Du, Mu-Le Tu, Yong-Xu Xia, Yuan-Qiang Lin, Rui Yang, Chang Weng, Yi Liu, Hao Zhang, Hui Wang, Wen-Jie Feng, Deng-Ke Teng.  (2026)  Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapy.  JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,      [PMID:42116166] [10.1186/s13046-026-03726-2]
Solution Calculators
Reviews

Customer Reviews

Need help choosing the grade?

Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.

View Moligand™ grade guide →

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.